QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Price, News & Analysis

$10.30
+0.19 (+1.88%)
(As of 02/22/2024 ET)
Today's Range
$9.75
$10.34
50-Day Range
$8.60
$10.51
52-Week Range
$7.72
$27.48
Volume
1.22 million shs
Average Volume
1.10 million shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.25

Vir Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
232.5% Upside
$34.25 Price Target
Short Interest
Healthy
6.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Vir Biotechnology in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$317,830 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.76) to ($4.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.06 out of 5 stars

Medical Sector

368th out of 934 stocks

Biological Products, Except Diagnostic Industry

55th out of 160 stocks


VIR stock logo

About Vir Biotechnology Stock (NASDAQ:VIR)

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

VIR Stock Price History

VIR Stock News Headlines

Shocking Bank Secret of the Ultra-Rich
A 229-year-old banking secret is behind some of the wealthiest, most powerful dynasties in American history –  here's how it could help you in 2024.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $34,007.04 in Stock
VIR Mar 2024 15.000 call
VIR Mar 2024 7.500 put
Vir Biotechnology (NASDAQ:VIR) PT Raised to $110.00
Vir Biotechnology (VIR) to Release Quarterly Earnings on Thursday
North American Morning Briefing: Microsoft Kicks -2-
Vir Biotechnology just downgraded at JPMorgan, here's why
Sticking With Vir Biotechnology
See More Headlines
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/03/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
576
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.25
High Stock Price Target
$110.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+232.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$515.84 million
Net Margins
-505.62%
Pretax Margin
-554.76%

Debt

Sales & Book Value

Annual Sales
$1.62 billion
Cash Flow
$3.89 per share
Book Value
$15.61 per share

Miscellaneous

Free Float
110,173,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
0.39
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Ann M. Hanly Ph.D. (Age 53)
    Executive VP & Chief Technology Officer
    Comp: $842.23k
  • Dr. Phillip Pang M.D. (Age 48)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $837.38k
  • Dr. Marianne De Backer M.B.A. (Age 54)
    M.Sc., Ph.D., CEO & Director
  • Dr. Klaus Frueh Ph.D. (Age 64)
    Co-Founder & Scientific Advisor
    Comp: $177.66k
  • Dr. Lawrence Corey M.D. (Age 77)
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Mr. Sung H. Lee (Age 54)
    Executive VP & CFO
  • Dr. Jennifer Eileen Towne Ph.D.
    Executive VP & Chief Scientific Officer
  • Ms. Heather Rowe Armstrong
    Vice President of Investor Relations
  • Ms. Vanina De Verneuil J.D.
    Executive VP, General Counsel & Corporate Secretary














VIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares.
View VIR analyst ratings
or view top-rated stocks.

What is Vir Biotechnology's stock price target for 2024?

7 equities research analysts have issued 12-month price targets for Vir Biotechnology's shares. Their VIR share price targets range from $9.00 to $110.00. On average, they anticipate the company's share price to reach $34.25 in the next year. This suggests a possible upside of 232.5% from the stock's current price.
View analysts price targets for VIR
or view top-rated stocks among Wall Street analysts.

How have VIR shares performed in 2024?

Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR stock has increased by 2.4% and is now trading at $10.30.
View the best growth stocks for 2024 here
.

When is Vir Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our VIR earnings forecast
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) released its earnings results on Thursday, August, 3rd. The company reported ($1.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by $0.24. The company earned $3.80 million during the quarter, compared to the consensus estimate of $22.39 million. Vir Biotechnology had a negative net margin of 505.62% and a negative trailing twelve-month return on equity of 31.89%. Vir Biotechnology's quarterly revenue was up 379999900.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.58) EPS.

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.14%), Baillie Gifford & Co. (2.95%), Bridgeway Capital Management LLC (1.00%), Northern Trust Corp (0.70%), Charles Schwab Investment Management Inc. (0.56%) and Goldman Sachs Group Inc. (0.43%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIR) was last updated on 2/22/2024 by MarketBeat.com Staff